论文部分内容阅读
目的:探讨肿瘤免疫治疗的临床价值,方法:回顾性研究我科近5a来以不同治疗方法,即单纯介入化疗(A组)、免疫治疗(B组)及介入化疗辅加免疫治疗(C组)、资料较完整,并得到随访的同期治疗患者200余例的治疗结果。结果:A、B、C组总有效率分别为28、6％、20、3％和44.6％。C组与B组相比,有显著差异(P<0.55)。在各组中,对不同肿瘤,其治疗效率略有差异,A、C组中以肺癌较高,B组中胃肠癌略高。短期生存率(半年)三组基本接近,分别为46、4％、44、8％、51.6％;而2～3a后的生存率C组明显高于A、B二组。机体免疫指标变化以辅助免疫治疗后明显,其中以SIL-2R下降x=(430.6±71.4)及NK细胞活力上升变化尤明显,与单纯介入化疗者相比,P<0、05及P<0.01,而吞噬细胞功能,IL-2R及IL-2表达,分泌水平无明显变化。结论:生物免疫治疗在中晚期恶性肿瘤的治疗中有积极意义及肯定的辅助疗效。
Objective: To investigate the clinical value of tumor immunotherapy. Methods: Retrospective study in our department for different treatment methods in the past 5 years, namely, simple interventional chemotherapy (group A), immunotherapy (group B) and interventional chemotherapy plus immunotherapy (group C) ), The data is more complete, and more than 200 cases of patients treated during the same period were followed up. Results: The total effective rates in groups A, B, and C were 28, 6%, 20, 3%, and 44.6%, respectively. There was a significant difference between group C and group B (P < 0.55). In each group, the treatment efficiency was slightly different for different tumors. Lung cancer was higher in group A and C, and gastrointestinal cancer was slightly higher in group B. The short-term survival rate (six months) was basically similar in the three groups: 46, 4%, 44, 8%, and 51.6%. The survival rate after 2 to 3 years in the C group was significantly higher than that in the A and B groups. Changes in body immune parameters were significantly improved after adjuvant immunotherapy, with a decrease in SIL-2R of x=(430.6±71.4) and a significant increase in NK cell viability. P<0, 05, and P<0.01 compared with those with simple intervention chemotherapy. , While phagocyte function, IL-2R and IL-2 expression, secretion levels did not change significantly. Conclusion: Biological immunotherapy has positive significance and affirmative adjuvant effect in the treatment of advanced malignant tumors.